Day One Biopharmaceuticals sets IPO terms

Child-cancer drug firm Day One Biopharmaceuticals (Nasdaq:DAWN) unveiled terms for its IPO that will offer 8.4 million shares at $14-$16 apiece. That values the firm at up to $960 million.
Read More